Virginie Sophie Poncelet

This inventor holds 37 USPTO granted patents and 7 published patent applications, plus 14 CIPO patents and 14 EPO patents, primarily in Cancer Therapeutics. Top assignees: Janssen Pharmaceutica Nv, Astex Therapeutics Limited. Active years: 2001-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Virginie Sophie Poncelet. Retrieved from https://idiyas.com/inventor/virginie-sophie-poncelet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 37 (Patent Applications = 7)

% Patents Active = 83.8

CIPO Patents = 14 (Patent Applications = 7)

EPO Patents = 14 (Patent Applications = 16)

Average Co-Inventor Count = 6.6

ph-index = 13

Forward Citations = 387(Granted Patents)

Location History:

Le Manior sur Seine, FR (2007)
Le Manier sur Seine, FR (2010 - 2013)
Le Marier sur Seine, FR (2014)
Val de Reuil, FR (2016)
Le Manoir, FR (2016 - 2018)
Le Nanoir, FR (2016 - 2019)
Issy-les Moulineaux, FR (2021 - 2022)
Le Manoir sur Seine, FR (2001 - 2023)

Company Filing History:

30 out of 2,101

Janssen Pharmaceutica Nv

patents

7 out of 126

Astex Therapeutics Limited

patents

Years Active: 2001-2023

Loading Chart...

Areas of Expertise:

MDM2 Inhibitors

P53 Interaction

FGFR Kinase

Histone Deacetylase

PI3K Inhibitors

Quinazoline Derivatives

Anti-Proliferative Agents

Farnesyl Transferase

Azaindoline Derivatives

Macrocyclic Compounds

Pyridine Derivatives

Imidazopyridazine

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11583524 - Inhibitors of the interaction between MDM2 and P53 (2023-02-21),

2. 11396517 - Exo-aza spiro inhibitors of menin-MLL interaction (2022-07-26),

3. 11236084 - Substituted azaindoline derivatives as NIK inhibitors (2022-02-01),

4. 11180487 - Substituted cyanoindoline derivatives as NIK inhibitors (2021-11-23),

5. 10894793 - Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors (2021-01-19),

6. 10272087 - Pteridines as FGFR inhibitors (2019-04-30),

7. 10208062 - Macrocyclic quinazole derivatives and their use as MTKI (2019-02-19),

8. 10202387 - Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors (2019-02-12),

9. 10087187 - Imidazopyridazine derivatives as PI3KB inhibitors (2018-10-02),

10. 10052320 - Substituted quinoxalines as FGFR kinase inhibitors (2018-08-21),

11. 10045982 - Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors (2018-08-14),

12. 9688691 - Macrocyclic quinazole derivatives and their use as MTKI (2017-06-27),

13. 9573933 - Inhibitors of the interaction between MDM2 and P53 (2017-02-21),

14. 9533979 - Amino-derivatives as novel inhibitors of histone deacetylase (2017-01-03),

15. 9493426 - Quinazolinone derivatives useful as FGFR kinase modulators (2016-11-15),

Title: Virginie Sophie Poncelet - Innovator in Pharmaceutical Patents

Introduction

Virginie Sophie Poncelet is a notable inventor based in Le Manoir sur Seine, France. With an impressive portfolio of 37 patents, she has made significant contributions to the field of pharmaceuticals. Her innovative work focuses on developing compounds that are instrumental in treating severe diseases.

Latest Patents

Among her latest patents, one includes inhibitors of the interaction between MDM2 and P53. This invention provides compounds of formula (I) designed to inhibit the p53-MDM2 interaction, as well as pharmaceutical compositions comprising these compounds. The patent details specific variables including n, m, p, s, t, R, and others, which have defined meanings crucial for understanding the complexity of the compounds.

Another significant patent is for Exo-aza spiro inhibitors of the menin-MLL interaction. This invention offers compounds of Formula (I), pharmaceutical compositions that include such compounds, and their utilization as inhibitors of the menin/MLL protein/protein interaction. This innovation is particularly beneficial for treating diseases such as cancer, myelodysplastic syndromes (MDS), and diabetes.

Career Highlights

Virginie Sophie Poncelet has gained valuable experience working with leading companies in the pharmaceutical sector, including Janssen Pharmaceutica and Astex Therapeutics Limited. Her work at these organizations has not only advanced her professional journey but also facilitated her groundbreaking innovations.

Collaborations

Throughout her career, Virginie has collaborated with esteemed professionals in her field. Notable coworkers include Lieven Meerpoel and Olivier Alexis Georges Querolle, who have contributed to her research and development efforts.

Conclusion

Virginie Sophie Poncelet continues to be a driving force in pharmaceutical innovation. With her extensive patent portfolio and collaborations with leading industry professionals, she is well-positioned to make further advancements that could improve treatment options for critical health issues. Her dedication to research and innovation exemplifies the vital role of inventors in shaping the future of medicine.

Profile summary based on public USPTO records.